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Abstract
Background: Currently dengue viruses (DENV) pose an increasing threat to over 2.5 billion people in over 100 tropical and
sub-tropical countries worldwide. International air travel is facilitating rapid global movement of DENV, increasing the risk of
severe dengue epidemics by introducing different serotypes. Accurate diagnosis is critical for early initiation of preventive
measures. Different reverse transcriptase PCR (RT-PCR) methods are available, which should be evaluated and standardized.
Epidemiological and laboratory-based surveillance is required to monitor and guide dengue prevention and control
programmes, i.e., by mosquito control or possible vaccination (as soon as an effective and safe vaccine becomes available).
Objective: The purpose of the external quality assurance (EQA) study described is to assess the efficiency and accuracy of
dengue molecular diagnosis methods applied by expert laboratories.
Study Design: A panel of 12 human plasma samples was distributed and tested for DENV-specific RNA. The panel
comprised 9 samples spiked with different DENV serotypes (DENV-1 to DENV-4), including 10-fold dilution series of DENV-1
and DENV-3. Two specificity controls consisted of a sample with a pool of 4 other flaviviruses and a sample with
chikungunya virus. A negative control sample was also included.
Results: Thirty-seven laboratories (from Europe, Middle East Asia, Asia, the Americas/Caribbean, and Africa) participated in
this EQA study, and reports including 46 sets of results were returned. Performance among laboratories varied according to
methodologies used. Only 5 (10.9%) data sets met all criteria with optimal performance, and 4 (8.7%) with acceptable
performance, while 37 (80.4%) reported results showed the need for improvement regarding accomplishment of dengue
molecular diagnosis. Failures were mainly due to lack of sensitivity and the presence of false positives.
Conclusions: The EQA provides information on each laboratory’s efficacy of RT-PCR techniques for dengue diagnosis and
indicates for most laboratories an urgent need to improve sensitivity and specificity.
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Introduction
Dengue viruses (DENV) are transmitted by Aedes sp. mosquitoes
and are members of the Flaviviridae family, genus Flavivirus.D E N V
comprise four antigenically distinct serotypes (DENV1-4), which are
genetically quite distinct. Infection with one DENV serotype leads to
lifelong protection againsthomologouschallenge, but only brief cross-
protection against heterologous infection with a different serotype[1].
The four serotypes of DENV are the causative agents of one of
the most important arthropod-borne viral diseases in terms of
human morbidity and mortality. Several virus and host-specific
factors have been suggested to correlate with severe disease
outcomes, which are mostly associated with secondary infections
with a heterologous serotype[2] and/or infections with more
intrinsically virulent strains of the virus[3,4].
Epidemic dengue fever (DF) and dengue haemorrhagic fever
(DHF) have emerged as a public health problem in recent decades,
with the development of hyperendemicity (different DENV
serotypes overlapping in an spatiotemporal manner), in urban
and periurban centres of many tropical and subtropical countries.
Air travel is also facilitating the rapid global movement of DENV
and increasing the risk of DHF through the introduction of
different serotypes into new areas. Two and a half billion people
live in areas where the disease is endemic, and 50–100 million
cases of DF are estimated to occur every year, including 500,000
cases of the more severe illnesses, DHF and dengue shock
syndrome (DSS)[5].
The laboratory diagnosis of dengue relies on the use of several
methods detecting markers of DENV infection present in patient
serum. Definitive diagnosis of dengue rests on the detection of the
www.plosntds.org 1 October 2010 | Volume 4 | Issue 10 | e833infective virus, virus-encoded antigens, viral genomic RNA, or
virus-induced antibodies. PCR-based diagnosis techniques can be
more sensitive than viral culture, since they are able to readily
detect the dengue viruses during the acute phase of the disease,
and may assume an important role in dengue diagnosis, since
detection of IgM is not possible practically until defervescence[6].
Molecular diagnosis methods are usually rapid, sensitive, and
simple when correctly standardized and can be used for genome
detection in human clinical samples, biopsies, autopsy tissues, or
mosquitoes. However, specimens and RNA must be carefully
handled to avoid RNA degradation. Further, RT-PCR is highly
sensitive to amplicon contamination, and without proper controls
false-positive results may occur.
Different RT-PCR methods have been developed for detecting
and typing DENV, which vary somewhat in terms of the
amplified gene regions of the genome, in the ways they detect
RT-PCR products, and the virus-typing procedures. RT-PCR
methods for detecting dengue virus-infected Aedes mosquitoes in
the field may serve as an additional early warning monitoring
system for predicting dengue outbreaks [7]. Moreover, since a
change in serotype would be particularly important in bringing
about a surge in DF/DHF cases, molecular methods are further
advantageous in detecting the specific circulating serotypes both
in dengue-infected patients and in natural populations of
mosquitoes.
Aiming at the evaluation of the accuracy and estimation of the
quality of laboratory data for the molecular diagnosis and
surveillance of dengue, we have realised an external quality
assurance (EQA) activity which involved worldwide dengue
reference laboratories.
Materials and Methods
Participants
Laboratories in Europe (n=22), Middle-East Asia (n=1), Asia
(n=8), Africa (n=1), and the Americas/Caribbean (n=5)
participated in the EQA activity: Institut fu ¨r Virologie, Philips
Universita ¨t Marburg, Germany; Institut fu ¨r Virologie, Universi-
ta ¨tsklinikum Bonn, Germany; Institut fu ¨r Virologie, Medizinische
Universita ¨t Wien, Austria; CNR Associe ´ des Arbovirus IRBA-
Antenne Marseille-IMTSSA, France; Institut Pasteur, Centre de
Re ´ference des Arbovirus, Marseille, France; Centro Nacional de
Microbiologı ´a, Instituto de Salud Carlos III, Madrid, Spain;
Instituto Tecnolo ´gico ‘‘La Maran ˜osa’’, Madrid, Spain; Aristotle
University of Thessaloniki, School of Medicine Department of
Microbiology, Greece; Erasmus Medical Centre, Rotterdam, The
Netherlands; Spiez Biology Laboratory, Spiez, Switzerland;
Institut fu ¨r Klinische Mikrobiologie und Immunologie, St.
Gallen, Switzerland; University of Geneva, Laboratory of
Virology, Geneva, Switzerland; Army Medical Research Center,
Rome, Italy; Department of Infectious, Parasitic and Immuno-
mediated Diseases, Instituto Superiore di Sanita `, Rome, Italy;
Instituto Nazionale per le Malattie Infettive ‘‘L. Spallanzani’’,
Rome, Italy; Laboratory of Vector-borne Infections, Cantacuz-
zino Institut, Bucarest, Romania; Instituut voor Tropische
Geneeskunde, Centraal Laboratorium Klinische Biologie, An-
twerpen, Belgium; Haartman Institute, University of Helsinki,
Finland; Statens Serum Institut, Department of Virology,
Copenhagen, Denmark; ‘‘Be ´la Johan’’ National Center for
Epidemiology, Budapest, Hungary; Norwegian Institute of Public
Health, Oslo, Norway; National Reference Laboratory for
Arboviruses, National Institute of Public Health, Ostrava, Czech
Republic; National Centre for Zoonotic Viruses, Tel Hashomer;
Israel; Department of Laboratory Medicine, Tan Tock Senk
Hospital, Singapore; Department of Molecular Medicine, Na-
tional University Hospital, Singapore; Department of Pathology,
Singapore General Hospital, Singapore; Environmental Health
Institute, Singapore; Hospital for Tropical Diseases, Oxford
University Clinical Research Unit, Ho Chi Minh City, Vietnam;
Tropical Infectious Diseases and Education Center, University
Malay, Kuala-Lumpur, Malaysia; Institut Pasteur, Cambodia;
Special Pathogens Unit, NICD-NHLS, Sandringham, South
Africa; Caribbean Epidemiology Center (CAREC), Port of Spain,
Trinidad; Laboratorio de Flavivirus, Instituto Oswaldo Cruz,
FIOCRUZ, Rio de Janeiro, Brazil; Centro de Investigacio ´n en
Enfermedades Infecciosas, INER, Tlalpan, Mexico; Instituto
Nacional de Salud, Bogota ´, Colombia; Instituto Nacional de
Enfermedades Virales Humanas Dr. Julio Maiztegui, Pergamino,
Argentina.
The EQA was established and coordinated by the European
Network for the Diagnostics of ‘Imported’ Viral Diseases-
Collaborative Laboratory Response Network (ENIVD-CLRN)
which has previously coordinated EQA studies [8,9,10].
Specimen preparation and dispatch
Inactivated and stable DENV preparations were generated
from cell culture (Vero B4) supernatants of the 4 dengue serotypes:
DENV-1 VR344 (Thai 1958); DENV-2 VR345 (TH-36 strain);
DENV-3 VR216 (H87 strain); and DENV-4 VR217 (H241
strain). Viral cell supernatants were inactivated by heating for 1 h
at 56uC and gamma irradiation [25 kilogray (kGy)] to assure their
non-infectivity.
Sample preparations were tested by an in-house real-time
quantitative RT-PCR with a sensitivity threshold of 5 genome
equivalents per reaction (GE)/rxn (100 GE/ml sample). Intra-assay
and inter-assay variance of this method were determined as ,3%
and ,4%, respectively. The inactivated supernatant viral load was
estimated after heat inactivation and additionally after gamma
irradiation. The inactivated supernatants were diluted in serum
plasma to prepare a set of 9 positive samples which included 5 serial
10-fold dilution series of DENV-1 (7610
5 GE/ml to 70 GE/ml),
Author Summary
Dengue viruses (DENV) are the most widespread arthro-
pod-borne viruses which have shown an unexpected
geographic expansion, as well as an increase in the
number and severity of outbreaks in the last decades. In
this context, the accurate diagnosis and reliable surveil-
lance of dengue infections are essential. The laboratory
diagnosis of dengue relies on the use of several methods
detecting markers of DENV infection present in patient
serum. Molecular diagnosis methods are usually rapid,
sensitive, and simple when correctly standardized. More-
over, PCR-based diagnosis techniques are able to readily
detect DENV during the acute phase of the disease and
may assume an important role in dengue diagnosis and
surveillance. Different reverse transcriptase PCR (RT-PCR)
methods have been developed and are currently available
and should be standardized in each laboratory to maintain
high quality performance. In this work an External quality
assessment (EQA) activity has been carried out to evaluate
the accuracy and quality of laboratory data for the
molecular diagnosis and surveillance of dengue, which
involved worldwide dengue reference laboratories. In
conclusion, RT-PCR techniques for dengue diagnosis
applied by the participating laboratories demonstrated
the need of further improvement in most laboratories.
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4 GE/ml and 3610
3 GE/ml).
DENV-2 and DENV-4 inactivated supernatants were diluted with
human plasma to 10
5 GE/ml. Two further plasma samples were
prepared as specificity controls, one of them containing yellow fever
virus [YF (YF-17D strain)], West Nile virus [WN (New York)],
Japanese encephalitis virus [JE (strain SA-14-02)] and tick-borne
encephalitis virus [TBE (strain Absettarov)], and a second one
containing chikungunya virus [CHIK (strain Marseille LR 2006/
684-1)], a common differential diagnosis of DF. A negative control
plasma sample was also included (Table 1). Aliquots of 100 ml were
number-coded, freeze dried for 24 h (Christ, AlphaI-5, Hanau,
Germany) and stored at 4uC until dispatch.
Four different sets of test aliquots were tested before distribution
by the Robert Koch Institute (RKI), Berlin, Germany. After
reconstitution with 100 ml of water, samples were extracted using
the QIAamp viral RNA minikit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. DENV genome
copies present in the samples were estimated by an in-house real
time PCR and serotypes were confirmed by nested RT-PCR and
sequencing [11]. Additionally, the sample panel was analysed
independently by one expert laboratory (USAMC-AFRIMS,
Bangkok, Thailand) using an RT-PCR assay[12] and an in-house
quantitative real time RT-PCR. This laboratory was blinded to
sample contents before analysis.
A temperature/time-stability control of the EQA samples was
additionally performed at the RKI. A set of samples were placed at
room temperature for 1 month, analysed for maintenance of their
properties, and compared to a set of samples stored at 4uC.
The EQA panel was distributed to all participants with full
instructions. Samples were shipped at ambient temperature by
post to participating laboratories. Participants were requested to
resuspend the samples in 100 ml of water and to analyse the
material as serum samples for DENV molecular diagnosis. They
were requested to report their results, and any problems
encountered, as well as to provide information on the assay
details (RT-PCR method and extraction procedure) using a
common form included in the documentation.
Evaluation of the results
To assure anonymous participation, an individual numerical
identification code was assigned to the results sent by each
laboratory. This number was followed by a letter (a, b) when
different sets of results (more than one method) were sent.
The results were scored in reflection of sensitivity, specificity,
and correct serotyping. Two points were given for correct dengue-
positive results and correct serotyping. One point was given for
correct dengue-positive results without or incorrect type determi-
nation. False-negative or false-positive results were scored with no
points. Sample #14 (DENV-1; 70 GE/ml) was not considered for
scoring. Quantitative data were considered only informative about
the availability of this data.
Additionally, results were classified as optimal for diagnosis and
surveillance (full detection up to 10
3 GE/ml and serotyping results),
acceptable for diagnosis (full detection up to 10
3 GE/ml), or need of
improvement (failure to detect one or more DENV serotypes or
sensitivity below 10
3 GE/ml). Samples #4 (DENV1; 7E+02 GE/ml)
and #14 (DENV1; 70 GE/ml) were not considered for classification.
No false-positive results were allowed in virus-free samples.
Test results were sent out in an anonymous manner to all
participants.
Statistical analysis
Data collected were entered into Microsoft Excel (Microsoft
Corp., Bellingham, WA, USA) and analysed using SPSS 14.0 for
Windows. To project performance of a hypothetical average
laboratory, cumulative fractions of positive results reported for
each test sample of the 10-fold dilution series with DENV-1 were
correlated against RNA concentrations in samples and subjected
to probit analysis. Results with respect to categorised variables
were analysed by the Chi-square test. Parametric (independent
sample t-test and ANOVA) and non-parametric (Mann-Whitney
and Kruskall-Wallis) tests were used to estimate the influence of
the PCR format on the performance.
Results
Sixty-seven institutions involved in laboratory diagnostics of
DENV infection were invited to participate in this study. Invitees
were members of the International WHO DengueNet, the
ENIVD-CLRN, or national/regional dengue reference laborato-
ries. The study was announced as an EQA study on DENV
molecular diagnostic proficiency, which included certifying and
publishing the results in a comparative and anonymous manner.
Thirty-seven laboratories (response rate 55.2%) from 27
countries participated in the study. A total of 46 sets of results
were received (Table 1), including 9 double sets from laboratories
that used 2 methods each (sets 2ab, 4ab, 9ab, 17ab, 19ab, 23ab,
25ab, 28ab, 35ab).
A variety of tests were used for screening and identification of
DENV by participating laboratories; these included nested (n=15,
32.6%)[11,12,13,14,15,16] and hemi-nested (n=2, 4.3%) RT-
PCR [17], TaqMan (n=25, 54.3%) [13,14,18,19,20,21,22,23]
and SYBR Green (n=4, 8.7%)-based real time PCR (Table 2).
Different RNA extraction methods were reported by the
participating laboratories; QIAmp Viral RNA Minikit (QIAGEN)
[n=19, 51.4%], EZ1 Biorobot (QIAGEN) [n=2, 5.4%], QIAmp
UltraSens kit (QIAGEN) [n=1, 2.7%], RNeasy kit (QIAGEN)
[n=1, 2.7%], QIASymphony Viral RNA extraction kit (QIAGEN)
[n=1, 2.7%], Macherey Nagel (Du ¨ren, Germany) RNA virus kit
[n=1, 2.7%], NucliSens Easy Mag (BIOMERIEUX, Nu ¨rtingen,
Germany)[n=1,2.7%].Unfortunately,elevenlaboratories(29.7%)
did not report data on the extraction procedure.
Performance variedamong the laboratories accordingto whether
themethodologiesusedachievedafulloracceptableresult(Table1).
Only 5 out of 46 (10.9%) analyses reported met all criteria with
optimal performance; 4 out of 46 (8.7%) data sets achieved
acceptable results; and 37 out of 46 (80.4%) of the results reported
showed that there is room for improvement regarding DENV
diagnosis. In 22 cases non-optimal results were due to the failure to
identify one or more DENV serotypes: DENV-2 (lab nu19a);
DENV-3 (nu 5, 20, 18, 24, 33); DENV-4 (nu 29, 1, 19b, 25b, 9a, 37,
6, 11); DENV2 and DENV3 (nu 22, 34); DENV2 and DENV4 (nu
17b); DENV-3 and DENV-4 (nu 30, 23a); DENV-2, DENV-3 and
DENV-4 (nu 35a, 32); DENV-1, DENV-3 and DENV-2 (nu 35b);
one laboratory completely failed in the detection of positive DENV
samples (nu 26). Failures due to the presence of false positives were
present in 8 data sets (nu 21, 9a, 9b 27, 30, 16, 11, 35b).
The serial dilutions of DENV-1 (samples #2, #9, #12, #4, and
#14) and DENV-3 (samples #5 and #13) showed a clear
tendency of low sensitivity with increased dilution, this being the
major reason for non-acceptable results (Table 1). Samples #4
and #14 (700 and 70 GE/ml, respectively) were not considered in
the classification, assuming that a minimal detection of 7,000 GE/
ml should be achieved to perform a reliable DENV molecular
diagnosis. Only 47.7% (n=22) of the entries reported positive
results in detecting 7,000 GE/ml of DENV-1, and 36.3% (n=17)
of the data sets achieved a positive result in the 3,000 GE/ml
DENV-3 samples.
Dengue Molecular Diagnosis Quality Control
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www.plosntds.org 5 October 2010 | Volume 4 | Issue 10 | e833A probit analysis was performed using positive results reported
for each sample of the 10-fold DENV-1 dilution series correlating
with RNA concentrations in samples (Figure 1). The data
demonstrated that globally 50% of positive performance could
be expected in concentrations higher than 10
4 GE/ml (95%
confidence interval [CI] 23,110–32,000 GE/ml). A certainty of
95% was achieved for 5610
4 GE/ml (95% CI 41,760–57,500
GE/ml). This pointed to the need of improvement of the
laboratories’ capacity for achieving positive results in lower viral
loads, so the existence of false negatives in routine practice of
DENV diagnosis could be minimized.
A probit analysis of the correct results obtained, using TaqMan-
based real time PCR and RT nested PCR protocols, showed that 50%
of positive performance could be expected when viral genome
concentration in the sample is higher than 10
4 GE/ml (Table 2).
95% of certainty was achieved with TaqMan real time PCR and RT
nested PCR when more than 4.2610
6 GE/ml (95% CI [5.2610
5–
4610
8]) or 4610
6 GE/ml (95% CI [5.7610
5–3.6610
8]), respectively
were present in the sample (Table 2). T-test comparing the TaqMan
real time performance versus RT nested PCR and SYBR Green real
time RT-PCR did not reveal any significant difference in performance
for the applied methods. In general, the choice of the real-time PCR
format seemed to have no effect on the success of the analysis which is
mostly affected by the performance of the individual laboratories as
demonstrated by the wide range of the confidence intervals.
As many as 9 laboratories (nu 2, 17, 28, 19, 9, 4, 25, 35, and 23)
used two different RT-PCR techniques for the evaluation. This
approach is advantageous to exclude false positives/negatives in
routine diagnosis. One laboratory used two different TaqMan
PCRs (17ab), one laboratory used a combination of TaqMan- and
SYBR Green-based PCRs (23a,b), one laboratory used two
different RT nested PCR techniques (35a,b); and six laboratories
used a combined approach of TaqMan real time PCR and RT
nested PCR (2a,b; 19a,b; 25a,b; 9a,b; 28a,b; 4a,b).
Table 2. Probit analysis of the sensitivity profile of the different RT-PCR methods reported.
Method used
for RT-PCR Protocols Percentage Low sensitivity#
Positive performance*
50% [CI 95%]
Positive performance*
95% [CI 95%]
RT nested PCR [12], [14], [11],l[13], [15], [16],a 32.6% (15/46) 80% (12/15) 10
4 GE/ml
[3610
324.2610
4 GE/ml]
4610
6 GE/ml
[5.7610
523.6610
8 GE/ml]
RT heminested PCR [17] 4.3% (2/46) 50% (1/2) NP NP
TaqMan
real time PCR
[12],[[14,18], [14], [19–20], [21],
[13],[22],[23],a; b
54.3% (25/46) 76% (19/25) 10
4GE/ml
[2.8610
324610
4 GE/ml]
4.2610
6GE/ml
[5.2610
524.4610
8GE/ml]
SYBR Green
real time PCR
[18], [29],a 8.6% (4/46) 50% (2/4) 6.3610
4GE/ml.
[NP]
3610
5 GE/ml
[NP]
NP: Not enough data for statistical analysis; a: in-house protocol; b: Commercial kit;
*Probit analysis.
# Sensitivity below 10
3 GE/ml.
Data fit into the model with p,0.05.
doi:10.1371/journal.pntd.0000833.t002
Figure 1. Probit analysis of data sets with a correct result (y axis) for DENV-1 related to viral RNA concentration in positive samples
(x axis). Data points represent individual samples in the panel. The thick line is the regression line calculated on the basis of a probit model (dose-
response curve), and thin lines are 95% confidence intervals. Data fit into the model with p,0.003.
doi:10.1371/journal.pntd.0000833.g001
Dengue Molecular Diagnosis Quality Control
www.plosntds.org 6 October 2010 | Volume 4 | Issue 10 | e833Only 26 data sets (56.5%) included serotyping results that are
necessary for achieving optimal results and support the reliability
of the techniques and the laboratories to perform both diagnosis
and surveillance activities.
Further information on the number of copies of DENV strains
referred to the participants was requested to estimate the
experience in viral load determination in DENV diagnosis. Only
8 laboratories out of 37 (21.6%) reported quantitative results (data
not shown), even though as many as 29 laboratories (78.4%) were
using real time-based procedures which would have allowed
obtaining this information.
Results reported from different laboratories using the same
techniques differed in their final performance, probably due to
differences in the individual operational procedures and not to
limitations of the methods themselves (Table 1). This is the case of
6 laboratories which reported data obtained using the TaqMan
PCR developed by Drosten et al[19], where a different
competence was observed depending on the reporting laboratory.
On the other hand, in some cases, the same limitations were
observed in laboratories using a common technique, thus
indicating that an improvement or up-dating of the technique
might be needed. This is the case of those laboratories using a
TaqMan PCR from Leparc-Gofart et al[21] which failed to detect
DENV-3 (Table 1).
A stability assessment of the samples when stored at room
temperature (23–25uC) for 1 month (Table 3) demonstrated that
the failure in detecting the DENV RNA experienced by some
laboratories was probably not due to genome degradation caused
by shipment conditions.
Some non-optimal results were due to the presence of false
positives even when a good profile of sensitivity and thus a high
score was reached (nu 21, 9b). False positives were mostly found on
sample #11, containing other flaviviruses like Japanese enceph-
alitis, yellow fever, West Nile and tick-borne encephalitis virus.
Of 13 laboratories taking part in the first DENV molecular
diagnosis EQA realised in 2003[9], eight laboratories participated
in the present EQA. Four laboratories improved their percentage
of correct results, three experienced a decrease, and 1 laboratory
reached 100% of correct results in both EQAs (data not shown).
Discussion
EQA studies for laboratory molecular diagnostics of DENV
help to monitor the quality and accuracy of current diagnosis and
the capacity for surveillance of the participating centres, to
highlight problems in particular techniques or specific laboratories,
and to give advice and assurance to all the centres. This is the
second DENV molecular diagnosis EQA under the auspices of the
ENIVD-CLRN project[9].
Twenty-two laboratories out of 37 (59.4%) participants were
located in Europe, a non-endemic area. Even though the EQA
was announced widely to national and international public health
institutions involved in dengue control and surveillance in endemic
areas, the number of responses was not as abundant as expected.
Among the reasons for that, we should consider the cost of the
reagents to be consumed for the exercise and to be covered by the
individual laboratories, or the unwillingness to send incorrect
results. Even though, it has to be considered that laboratories in
endemic countries, that may not have participated in this EQA but
perform dengue molecular diagnosis routinely, usually have strong
internal quality control programs, and there are numerous
laboratories that do perform internal QC procedures. Participa-
tion in EQA diagnosis activities must be encouraged and
supported by health institutions as they provide helpful informa-
tion on the capabilities of the health system to detect and control
the disease.
In the present study the performance of molecular methods for
DENV diagnosis with different designs varies depending on the
method and the reporting laboratory. It is difficult to assess which
methods are better, since primers, enzymes, buffers, reaction
conditions, genome target, and thermocyclers can all influence the
reliability of a PCR[24]. However, some conclusions could be
assumed from the results obtained in this EQA.
Surprisingly, a low sensitivity was appreciated in the general
results of this EQA, even when reliable real time procedures were
used. We selected a cut-off of $10
3 GE/ml to achieve an optimal
or acceptable classification because it is considered over the above
limit of detection of current RT-PCR protocols [6]. Secondly, we
have also assumed this to be a suitable detection threshold for
diagnosis of acute dengue according to published results on viral
load titers in DF and DHF patients [25,26,27]. Extreme
precaution should be taken when performing molecular diagnosis
using methods with a limited sensitivity, so it could suppose the
presence of false negatives in the diagnostic results. Likewise, in the
final classification, no false positives results were allowed in virus-
free samples, and the inability to detect one or more DENV
serotypes was also considered non-acceptable, as this could lead to
an incorrect DENV diagnosis with high impact on the clinical and
public health management of DENV cases. In our study, false
positives were found mainly in sample #11, which contained viral
genome of different flaviviruses (Japanese encephalitis virus, tick-
borne encephalitis virus, West Nile virus, and yellow fever virus).
This reflects the need for further improvement on the specificity of
the methodologies and/or the procedures carried out in the
laboratories to avoid cross-contamination.
The sets of samples were sent by post to the participating
laboratories, and it was of concern in some cases that it took long
for them to reach their destination while maintained at ambient
temperature. We tested the stability of the samples when stored at
room temperature and demonstrated that genome degradation
caused by shipment conditions was minimal.
In this study, a clear significant difference in sensitivity could not
be noted when real time RT-PCR procedures were compared to
Table 3. Stability of the lyophilized panel of samples.
#2 #9 #12 #4 #14 #5 #13 #6 #10
DEN-1 DEN-1 DEN-1 DEN-1 DEN-1 DEN-3 DEN-3 DEN-2 DEN-4
7610
5 7610
4 7610
4 NEG NEG 2610
4 1610
3 6610
4 1610
5 GE/ml 4uC
4610
4 1.4610
4 1610
3 90 NEG 1.5610
4 2610
3 7.3610
4 1610
5 GE/ml RT
A set of YF EQA samples were kept at room temperature (23–25uC) for 1 month. These samples were analysed in parallel with a control set of samples kept at 4uC using
an in-house real-time RT-PCR to control the level of stability/degradation of the samples when sent by mail at room temperature.
doi:10.1371/journal.pntd.0000833.t003
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www.plosntds.org 7 October 2010 | Volume 4 | Issue 10 | e833RT-nested or heminested-PCR protocols, so no conclusions can
be ventured in this regard. It should be said, however, that the
most important factor in the reliability of the results for dengue
diagnosis is the individual performance of each laboratory, as
demonstrated by the different score values reached by different
laboratories that used the same published protocols. This should
alert to the need to revise the running protocols and processes in
those laboratories without good results.
Different extraction methods have been reported, with most of
the laboratories using QIAGEN kits for viral RNA extraction.
Unfortunately, we did not receive this information from all
laboratories, so we could not perform an accurate statistical
analysis. However, in previous EQAs, the extraction procedures
showed no great relevancy regarding final performance[9].
Discrepancies due to the reporting of an incorrect serotype were
considered acceptable for diagnosis, since the case management
would not have been affected. However, the absence of serotyping
procedures or non-reliable ones diminished the possibility of
performing surveillance studies. In those laboratories in non-
endemic areas where dengue is diagnosed in the context of an
‘‘imported’’ disease (i.e. European laboratories), serotype classifi-
cation of the cases could be considered unnecessary for clinical
management of the patients, whereas in DENV-endemic countries
it is highly desirable for reference laboratories to contribute
serotype information, since established surveillance systems should
monitor where DENV is transmitted, which serotypes are
involved, and which type of illness is associated with these
serotypes.
Quantification of DENV RNA in human plasma samples can
provide more clues for performing pathogenesis studies and
monitoring the progress of clinical manifestations [25,26,27]. The
use of different quantitative real time PCRs has been reported on
this EQA, and 29 different data sets were obtained using these
techniques. However, the absence of quantification data in most of
participating laboratories is remarkable.
In order to improve awareness and technical performance of
DENV reference laboratories, we recommend the continuation of
these EQA exercises.
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